Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
| Current Price | ₹7.68 |
|---|---|
| Market Cap | ₹38 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | -1.1 |
| Return on Equity | -51.13% |
| 52-Week Range | ₹5.67 – ₹14.20 |
| Beta (1Y) | 1.85 |
| Dividend Yield | 3.26% |
Lasa Supergenerics Ltd is trading at ₹7.68, with a market capitalisation of ₹38 Cr.
Lasa Supergenerics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Lasa Supergenerics Ltd has a P/E of -1.1 and a return on equity of -51.13%.